m/s / COVID-19
Open Access
Med Sci (Paris)
Volume 36, Number 6-7, Juin–Juillet 2020
m/s / COVID-19
Page(s) 633 - 641
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2020113
Published online 19 June 2020
  1. Vabret A, J. Dina J, Brison E, et al. Coronavirus humains (HCoV). Pathol Biol 2009 ; 57 : 149–160. [CrossRef] [PubMed] [Google Scholar]
  2. De Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016 ; 14 : 523–534. [CrossRef] [PubMed] [Google Scholar]
  3. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382 : 929–36. [Google Scholar]
  4. Masters PS. The molecular biology of coronaviruses. Adv Virus Res 2006 ; 66 : 193–292. [Google Scholar]
  5. Neuman BW, Chamberlain P, Bowden F, et al. Atlas of coronavirus replicase structure. Virus Res 2014 ; 194 : 49–66. [CrossRef] [PubMed] [Google Scholar]
  6. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 2009 ; 2009 : 7 439–450. [Google Scholar]
  7. Bos EC, Luytjes W, Van der Meulen H, Koerten HK, et al. The production of recombinant infectious DI-particles of a murine coronavirus in the absence of helper virus. Virology 1996 ; 218 : 52–60. [CrossRef] [PubMed] [Google Scholar]
  8. De Haan CAM, Rottier PJM. Molecular interactions in the assembly of coronaviruses. Adv Virus Res 2005 ; 64 : 165–230. [Google Scholar]
  9. Mercadier JJ. Une seconde enzyme de conversion de l’angiotensine juste pour le cœur ?. Med Sci (Paris) 2003 ; 19 : 141–143. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  10. Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res 2015 ; 202 : 120–134. [CrossRef] [PubMed] [Google Scholar]
  11. Hagemeijer MC, Rottier PJM, de Haan CAM. Biogenesis and dynamics of the coronavirus replicative structures. Viruses 2012 ; 4 : 3245–3269. [CrossRef] [PubMed] [Google Scholar]
  12. Alperovitch A, Lazar P. L’éthique des essais thérapeutiques. Med Sci (Paris) 2020; 36 : 303–7. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  13. Amiel P, Chneiweiss H, Dosquet C. Covid-19 : protocoles de soins ou protocoles de recherche ? Med Sci (Paris) 2020; 36 : 521–3. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  14. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016 ; 531 : 381–385. [CrossRef] [PubMed] [Google Scholar]
  15. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; doi.org/10.1016/S0140-6736(20)31022–9. [Google Scholar]
  16. Barragan P, Podzamczer D. Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment. Expert Opin Pharmacother 2008 ; 9 : 2363–2375. [CrossRef] [PubMed] [Google Scholar]
  17. Wu CY, Jan JT, Ma SH, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci USA 2004 ; 101 : 10012–10017. [CrossRef] [Google Scholar]
  18. Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 2013 ; 23 : 300–302. [CrossRef] [PubMed] [Google Scholar]
  19. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 105949. doi : 10.1016/j.ijantimicag.2020.105949. [CrossRef] [PubMed] [Google Scholar]
  20. Netea MG, Domínguez-Andrés J, Barreiro LB, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol 2020. doi : 10.1038/s41577-020-0285-6. [Google Scholar]
  21. Domingo E.. Mechanisms of viral emergence. Vet Res 2010 ; 41 : 38. [CrossRef] [PubMed] [Google Scholar]
  22. Tripathy S, Dassarma B, Roy S, et al. A review on possible modes of actions of Chloroquine/ Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic. Int J Antimicrob Agents 2020 May 22 :106028. doi: 10.1016/j.ijantimicag.2020.106028. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.